Leerink raised the firm’s price target on HCA Healthcare to $396 from $367 and keeps an Outperform rating on the shares. The firm notes Q2 results brought forth a continuation of positive trends anchored to above average volume growth, strong pricing/mix, favorable redetermination impacts, more DPP and strong cost controls. The Q2 upside and guide was driven by DPP and core outperformance, Leerink adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA: